File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hepatitis B infection in patients with lymphomas

TitleHepatitis B infection in patients with lymphomas
Authors
Issue Date1990
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1990, v. 8 n. 5, p. 261-270 How to Cite?
AbstractThis paper reviewed the clinical characteristics and treatment outcome of 484 lymphoma patients with known hepatitis B status. Comparisons were made between the hepatitis B surface antigen positive and negative patients. Also, the effect of treatment for lymphomas, including cytotoxic chemotherapy, in the hepatitis B antigen positive patients were analysed. The hepatitis B status was determined in 484 Chinese lymphoma patients at the time of initial diagnosis. Hepatic complications occurring during therapy for lymphomas were analysed. Although our lymphoma patients had a similar prevalence of hepatitis B markers of 42 per cent, they had a strikingly higher positive rate of 22 per cent for hepatitis B surface antigen and a relatively lower positive rate of 20 per cent for antibody, as compared to the respective figures of 9.5 per cent and 33 per cent in the control population. The hepatitis B surface antigen positive patients were younger than the negative patients but their treatment outcomes were similar despite the higher incidence of hepatic complications (21 per cent) in the hepatitis B surface antigen positive patients during therapy for lymphomas. None of the clinical parameters analysed appeared to be useful in predicting the development of these complications which included fatal liver failure (5.7 per cent), icteric hepatitis (5.7 per cent) and anicteric hepatitis (9.5 per cent). The high prevalence of hepatitis B surface antigen in our lymphoma patients may be related to the immunosuppressive effect of lymphomas. There is no definite evidence to suggest that hepatitis B infection has an aetiological or promoting role in the pathogenesis of lymphomas. Hepatitis B infection has contributed to the high incidence of hepatic complications during therapy for lymphomas and possible ways of prevention need to be investigated.
Persistent Identifierhttp://hdl.handle.net/10722/161834
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, RHSen_US
dc.contributor.authorLok, ASFen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorTodd, Den_US
dc.contributor.authorChiu, EKWen_US
dc.date.accessioned2012-09-05T05:15:23Z-
dc.date.available2012-09-05T05:15:23Z-
dc.date.issued1990en_US
dc.identifier.citationHematological Oncology, 1990, v. 8 n. 5, p. 261-270en_US
dc.identifier.issn0278-0232en_US
dc.identifier.urihttp://hdl.handle.net/10722/161834-
dc.description.abstractThis paper reviewed the clinical characteristics and treatment outcome of 484 lymphoma patients with known hepatitis B status. Comparisons were made between the hepatitis B surface antigen positive and negative patients. Also, the effect of treatment for lymphomas, including cytotoxic chemotherapy, in the hepatitis B antigen positive patients were analysed. The hepatitis B status was determined in 484 Chinese lymphoma patients at the time of initial diagnosis. Hepatic complications occurring during therapy for lymphomas were analysed. Although our lymphoma patients had a similar prevalence of hepatitis B markers of 42 per cent, they had a strikingly higher positive rate of 22 per cent for hepatitis B surface antigen and a relatively lower positive rate of 20 per cent for antibody, as compared to the respective figures of 9.5 per cent and 33 per cent in the control population. The hepatitis B surface antigen positive patients were younger than the negative patients but their treatment outcomes were similar despite the higher incidence of hepatic complications (21 per cent) in the hepatitis B surface antigen positive patients during therapy for lymphomas. None of the clinical parameters analysed appeared to be useful in predicting the development of these complications which included fatal liver failure (5.7 per cent), icteric hepatitis (5.7 per cent) and anicteric hepatitis (9.5 per cent). The high prevalence of hepatitis B surface antigen in our lymphoma patients may be related to the immunosuppressive effect of lymphomas. There is no definite evidence to suggest that hepatitis B infection has an aetiological or promoting role in the pathogenesis of lymphomas. Hepatitis B infection has contributed to the high incidence of hepatic complications during therapy for lymphomas and possible ways of prevention need to be investigated.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_US
dc.relation.ispartofHematological Oncologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAge Factorsen_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Adverse Effectsen_US
dc.subject.meshBleomycin - Administration & Dosageen_US
dc.subject.meshChilden_US
dc.subject.meshCyclophosphamide - Administration & Dosageen_US
dc.subject.meshDexamethasone - Administration & Dosageen_US
dc.subject.meshDoxorubicin - Administration & Dosageen_US
dc.subject.meshDrug-Induced Liver Injury - Etiologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B - Complicationsen_US
dc.subject.meshHepatitis B Surface Antigens - Immunologyen_US
dc.subject.meshHumansen_US
dc.subject.meshLeucovorin - Administration & Dosageen_US
dc.subject.meshLiver - Drug Effectsen_US
dc.subject.meshLymphoma - Complications - Immunology - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMethotrexate - Administration & Dosageen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrednisone - Administration & Dosageen_US
dc.subject.meshVincristine - Administration & Dosageen_US
dc.titleHepatitis B infection in patients with lymphomasen_US
dc.typeArticleen_US
dc.identifier.emailLiang, RHS:rliang@hku.hken_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLiang, RHS=rp00345en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/hon.2900080504en_US
dc.identifier.pmid1701155-
dc.identifier.scopuseid_2-s2.0-0025202725en_US
dc.identifier.volume8en_US
dc.identifier.issue5en_US
dc.identifier.spage261en_US
dc.identifier.epage270en_US
dc.identifier.isiWOS:A1990EK90200003-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLiang, RHS=26643224900en_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US
dc.identifier.scopusauthoridChiu, EKW=24827833600en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats